Aeon Biopharma Inc

Aeon Biopharma Inc（AEON）股票分析

$0.174

+0.018 (+10.06%)收盤時

Loading chart…
最高
0.185
開盤
0.160
成交量加權均價
0.17
成交量
895.53K
市值
41.47M
最低
0.151
成交金額
152.27K
企業價值/稅息折舊攤銷前利潤（TTM）
0.00

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed enrollment and dosing of patients for a Phase II double blind study of ABP-450 for the treatment of both chronic and episodic migraine.

aeonbiopharma.com

AI 分析 of Aeon Biopharma Inc (AEON)

持有

Aeon Biopharma Inc is currently a hold due to its low price of $0.17, which is significantly below its 52-week high of $1.45, indicating potential upside. However, the RSI is at 29.072, suggesting the stock is oversold, but it has experienced a drastic decline of 84.32% year-to-date, raising concerns about its stability. Analysts have set a price target of $2, reflecting optimism about the company's FDA feedback on ABP-450, but the risk of further losses remains high, especially given the recent 5-day change of -36.50%.

估值指標

Aeon Biopharma Inc（AEON）目前預期本益比為 1.16，5 年平均預期本益比為 -0.47。

預期本益比

合理
5 年均值 P/E
-0.47
目前P/E
1.16
高估
3.95
低估
-4.89

預期 EV/EBITDA

嚴重低估
5 年均值 EV/EBITDA
0.00
目前EV/EBITDA
0.00
高估
0.00
低估
0.00

預期股價營收比

嚴重高估
5 年均值 P/S
1.31
目前P/S
23.96
高估
6.71
低估
-4.09

Alphio AI 對 AEON 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。

樂

樂觀

樂觀 · 25%AEON

$1.02

情境價格

基

基準

基準 · 50%AEON

$0.94

情境價格

悲

悲觀

悲觀 · 25%AEON

$0.85

情境價格

事件時間軸

2026-09-30 (ET)

08:30:00

AEON Biopharma Receives FDA Meeting Minutes

2026-08-24 (ET)

08:30:00

Aeon Biopharma Appoints Paul Lee as Acting Chief Regulatory Officer

2026-07-14 (ET)

10:30:00

Aeon Biopharma Prices Public Offering to Raise Up to $43.3M

2026-04-05 (ET)

21:20:00

AEON Biopharma Receives NYSE Warning

2026-03-25 (ET)

08:20:00

Aeon Biopharma Receives FDA Feedback to Advance ABP-450 Development

查看更多事件

資訊

查看更多資訊

AEON 常見問題 —— 由 Alphio AI 解答

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed enrollment and dosing of patients for a Phase II double blind study of ABP-450 for the treatment of both chronic and episodic migraine. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Aeon Biopharma Inc is currently a hold due to its low price of $0.17, which is significantly below its 52-week high of $1.45, indicating potential upside. However, the RSI is at 29.072, suggesting the stock is oversold, but it has experienced a drastic decline of 84.32% year-to-date, raising concerns about its stability. Analysts have set a price target of $2, reflecting optimism about the company's FDA feedback on ABP-450, but the risk of further losses remains high, especially given the recent 5-day change of -36.50%.

社群

更多 ↗
分享你對 AEON 的看法
發布
cursedslot2026/10/30

$RED $AEON $FUN I never imagined I would reach $270k through crypto trading, but my experience with Craig's guidance has been a big part of my journey. I appreciate his insights, patience, and the way he approaches the market. His advice has helped me become more disciplined and confident in my trading decisions. Honestly, Craig is someone I genuinely recommend to anyone serious about improving their crypto trading skills. I've learned a lot from following Craig's crypto trading insights. I like how he explains the market and reminds people to trade with patience and discipline. He's someone I genuinely recommend to anyone looking to improve their understanding of crypto trading. If you are interested in crypto trading and want someone whose insights can encourage you to think more carefully about the market, I believe Craig is worth checking out. I have a lot of respect for his approach, and I genuinely appreciate what I have learned from following him.

展開
$ AEON$ RED$ FUN
00
OmegaGambler2026/10/23

$WARD $AEON $RIVER I've learned a lot from following Craig's crypto trading insights. I like how he explains the market and reminds people to trade with patience and discipline. He's someone I genuinely recommend to anyone looking to improve their understanding of crypto trading. $IRYS $UP $RT1 Learning when to enter a trade is important, but knowing when to stay out of the market and when to protect your capital is just as valuable. These are lessons every serious trader should take time to understand. I made $40,000 today, so I highly recommend it.

展開
$ AEON$ RIVER$ WARD
00
rustywalker2026/10/18

$AEON so far has $17.5M in volume. Could Julie be accumulating at the bottom and preparing for a sharp move up? After all, the current leader is making a fortune.

展開
$ AEON
00
註冊或登入後參與討論

相關文章

本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易